Autocrine CCL5 effect mediates trastuzumab resistance by ERK pathway activation in HER2-positive breast cancer

Autor: Zazo S, Gonzalez-Alonso P, Martin-Aparicio E, Chamizo C, Luque M, Sanz-Alvarez M, Minguez P, Gomez-Lopez G, Cristobal I, Carames C, Garcia-Foncillas J, Eroles P, Lluch A, Arpi O, Rovira A, Albanell J, Madoz-Gurpide J, Rojo F

Publikováno v: MOLECULAR CANCER THERAPEUTICS
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname

HER2-positive breast cancer is currently managed with chemotherapy in combination with specific anti-HER2 therapies, including trastuzumab. However, a high percentage of patients with HER2-positive tumors do not respond to trastuzumab (primary resist

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::d3a0ae64ea01e1c92d9da343bed95c2d
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=4444

Recent Insights into the Development of Preclinical Trastuzumab- Resistant HER2+ Breast Cancer Models.

Autor: Gonzalez-Alonso P; Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain., Cristobal I; Medical Oncology Department, Oncohealth Institute, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain., Zazo S; Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain., Martin-Aparicio E; Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain., Chamizo C; Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain., Madoz-Gurpide J; Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain., Rovira A; Cancer Research Program, Hospital del Mar Research Institute (IMIM), Medical Oncology Department, Hospital del Mar, E-08003 Barcelona, Spain., Eroles P; Oncology and Hematology Department, Health Research Institute University Clinic Hospital of Valencia (INCLIVA), University of Valencia, E-46010 Valencia, Spain., Lluch A; Oncology and Hematology Department, Health Research Institute University Clinic Hospital of Valencia (INCLIVA), University of Valencia, E-46010 Valencia, Spain., Albanell J; Cancer Research Program, Hospital del Mar Research Institute (IMIM), Medical Oncology Department, Hospital del Mar, E-08003 Barcelona, Spain., Rojo F; Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain.

Publikováno v: Current medicinal chemistry [Curr Med Chem] 2018; Vol. 25 (17), pp. 1976-1998.

Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines.

Autor: Sanz-Álvarez, Marta¹ (AUTHOR) marta.sanza@quironsalud.es, Luque, Melani¹ (AUTHOR) melani.luque@quironsalud.es, Morales-Gallego, Miriam¹ (AUTHOR) miriam.moralesg@quironsalud.es, Cristóbal, Ion² (AUTHOR) ion.cristobal@quironsalud.es, Ramírez-Merino, Natalia³ (AUTHOR) natalia.ramirezm@quironsalud.es, Rangel, Yamileth⁴ (AUTHOR) yamileth.rangel@quironsalud.es, Izarzugaza, Yann⁵ (AUTHOR) yizarzugaza@quironsalud.es, Eroles, Pilar^6,7 (AUTHOR) pilar.eroles@uv.es, Albanell, Joan^8,9,10 (AUTHOR) 96087@parcdesalutmar.cat, Madoz-Gúrpide, Juan¹ (AUTHOR) jmadoz@fjd.es, Rojo, Federico¹ (AUTHOR) jmadoz@fjd.es

Publikováno v: International Journal of Molecular Sciences. Jan2024, Vol. 25 Issue 1, p207. 23p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.